๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for ANCA Associated Vasculitis

The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome NCT07275190NA1 site๐Ÿ“ Pavia Fondazione IRCCS Policlinico San Matteo di Pavia ยท Tests: Blood draw for the laboratory assessment Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. NCT06581562Phase 11 site๐Ÿ“ Plantation IRIS Research and Development, LLC ยท Tests: AB-101, Rituximab, Cyclophosphamide, Fludarabine A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. NCT07203404EARLY Phase 11 site๐Ÿ“ Shanghai Nanjing Bioheng Biotech Co., Ltd. ยท Tests: RD06-05 CART Cell Injection An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646NA1 site๐Ÿ“ Shanghai China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 Rare AutoImmune SElf-management Programme Development NCT06642870n/a1 site๐Ÿ“ Bristol University of the West of England ยท Tests: Non-interventional study Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils NCT04538937n/a1 site๐Ÿ“ Innsbruck Medical University Innsbruck ยท Tests: no intervention Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases NCT06775912EARLY Phase 11 site๐Ÿ“ Lianyungang Nanjing Bioheng Biotech Co., Ltd. ยท Tests: RD06-05 CART Cell Injection Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD19- BCMA CAR-T cells CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: UCAR T-cell Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis NCT02257866n/a1 site๐Ÿ“ Bethesda National Institute of Arthritis and Musculoskeletal and Skiโ€ฆ A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases NCT06512883Phase 315 sites๐Ÿ“ Aurora๐Ÿ“ Cincinnati๐Ÿ“ Highland Hills AstraZeneca ยท Tests: Benralizumab Safety and Efficacy of Universal CD19-targeting CAR-ฮณฮดT Cells in Refractory Autoimmune Diseases NCT06828042Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University Third Hospital ยท Tests: anti-CD19 CAR T cell therapy Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases NCT06685042Phase 1, Phase 21 site๐Ÿ“ Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS ยท Tests: CAR T cell Benralizumab Effectiveness in EGPA NCT07815886n/a1 site๐Ÿ“ Florence European EGPA Study Group ยท Tests: Benralizumab 30 mg/ml CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: QT-019C A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NCT06733935Phase 1, Phase 218 sites๐Ÿ“ Orange๐Ÿ“ Gainesville๐Ÿ“ Miami Nkarta, Inc. ยท Tests: NKX019, Fludarabine, Cyclophosphamide BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: BCMA-CD19 CAR-T therapy CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease NCT07305116Phase 11 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ ยท Tests: UCAR T-cell VCRC Tissue Repository NCT02967068n/a8 sites๐Ÿ“ Boston๐Ÿ“ Boston๐Ÿ“ Cleveland University of Pennsylvania Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis NCT07010250n/a1 site๐Ÿ“ Paris Assistance Publique - Hรดpitaux de Paris A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site๐Ÿ“ Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 cell Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis NCT00315380n/a15 sites๐Ÿ“ San Diego๐Ÿ“ Denver๐Ÿ“ Boston University of Pennsylvania Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) NCT05962840Phase 41 site๐Ÿ“ Beijing Chinese SLE Treatment And Research Group ยท Tests: Telitacicept, Placebo of Telitacicept Rescue of Nephrons With ALE.F02 (RENAL-F02) NCT06047171Phase 253 sites๐Ÿ“ Prague๐Ÿ“ Prague๐Ÿ“ Aalborg Alentis Therapeutics AG ยท Tests: ALE.F02, Rituximab, GlucoCorticoid, Cyclophosphamid, Placebo A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease NCT06308978Phase 121 sites๐Ÿ“ Beverly Hills๐Ÿ“ Fullerton๐Ÿ“ Irvine Fate Therapeutics ยท Tests: FT819, Fludarabine, Cyclophosphamide, Bendamustine Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis NCT07160608Phase 278 sites๐Ÿ“ Ciudad de Buenos Aires๐Ÿ“ Ciudad de Buenos Aires๐Ÿ“ La Plata Alexion Pharmaceuticals, Inc. ยท Tests: Placebo, Tarperprumig Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease NCT07507201EARLY Phase 11 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ ยท Tests: UCAR T-cell A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis NCT06072482Phase 483 sites๐Ÿ“ Anchorage๐Ÿ“ Scottsdale๐Ÿ“ Surprise Amgen ยท Tests: Avacopan, Placebo, Standard of Care Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies NCT07251179n/a1 site๐Ÿ“ Strasbourg University Hospital, Strasbourg, France ยท Tests: blood draw A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis ๏ผˆEGPA๏ผ‰ NCT05979051Phase 2, Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Hangzhou Guangdong Hengrui Pharmaceutical Co., Ltd ยท Tests: SHR-1703, Mepolizumab Injection
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy